Pulnovo Medical has revealed impressive outcomes from the PADN-HF-PH trial, highlighting a breakthrough in managing pulmonary hypertension linked to left heart disease, now published in NEJM.

Nature Reviews Cardiology, Published online: 15 September 2026; doi:10.1038/s41569-026-01350-3Pulmonary artery denervation lowers the risk of clinical worsening in patients with pulmonary hypertension caused by left-sided heart disease and associated with heart failure who remain symptomatic despite treatment with guideline-directed medical therapy, according to findings from the PADN-HF-PH trial.

Pulnovo Medical unveiled significant results from the PADN-HF-PH study, demonstrating major advancements in treating pulmonary hypertension at ESC 2026.

Pulnovo Medical has announced pivotal results from its PADN-HF-PH clinical trial at ESC Congress 2026, revealing significant clinical improvements and groundbreaking findings.

Discover how Pulnovo Medical's PADN-HF-PH trial results showcased at ESC Congress 2026 promise revolutionary advancements in heart failure treatment, published in NEJM.

Pulnovo Medical announces impressive results from the PADN-HF-PH trial, showing significant clinical improvements in pulmonary hypertension. Key findings include a 51% reduction in clinical worsening risk.

Clinical outcomes from 264 PH-LHD patients demonstrate a 51% reduction in the risk of clinical worsening, a 35.5% decrease in recurrent clinical events, and sustained concurrent improvements in functional capacity, supporting the multi-dimensional therapeutic benefits of the Pulmonary...

SHANGHAI, 12. Sept. 2025 /PRNewswire/ -- Pulnovo Medical, ein weltweit anerkannter Marktführer im Bereich medizinischer Geräte für pulmonale Hypertonie (PH) und Herzinsuffizienz (HF), ist stolz darauf, bekanntzugeben, dass sein PADN-Katheter und -Generator zwei IDE-Zulassungen...

SHANGHAI, Sept. 12, 2025 /PRNewswire/ -- Pulnovo Medical, a globally recognized leader in medical devices for pulmonary hypertension (PH) and heart failure (HF), is proud to announce that its PADN catheter and generator has received two Investigational Device Exemption (IDE) approvals—HDE...

SHANGHAI, Sept. 12, 2025 /PRNewswire/ -- Pulnovo Medical, a globally recognized leader in medical devices for pulmonary hypertension (PH) and heart failure (HF), is proud to announce that its PADN catheter and generator has received two Investigational Device Exemption (IDE) approvals—HDE...